Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 694

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 694
---
 equity in lieu of cash) at the close of the Mergers but before the Closing Date by Kineta. This adjustment to the pro forma condensed combined balance sheet is assumed in order to satisfy the maximum net working capital deficit amount permissible of $6,000,000 pursuant to the Merger Agreement; as amended in April 2025. While the calculation of the net working capital deficit pursuant to the terms of the Merger Agreement using the historical financial information of Kineta as of December 31, 2024 would only be 5,872,781, which would be permissible under the amended Merger Agreement, the $1,432,943 of additional expenses expected to be incurred by Kineta subsequent to December 31, 2024 that are directly attributable to the Mergers result in an excess of over the $6,000,000 permitted as the net working capital deficit. Since $1,600,993 of Kineta’s transaction costs were expected to be paid in cash at the close of the Mergers, which would result in a direct increase to the net working capital deficit, in order to reflect a reduction in the expected deficit to the $6,000,000 permitted in the amended Merger Agreement, a pro forma adjustment was made to reflect the $1,305,724 excess of these costs that will be expected to be paid via issuance of Kineta stockholders’ equity prior to the Effective Time.

Using the closing stock price of Kineta as of April 21, 2025 of $0.28 to estimate the amount of Kineta common shares which would need to be issued in order to reduce the net working capital deficit to an amount allowed in the amended agreement, 4,663,300 shares would be expected to be issued to the vendors and employees to which the estimated transaction costs pertain in lieu of cash. Accordingly, the shares

<div align='center'>451</div>

### NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
**expected to be issued are reflected through the $4,663 adjustment to Kineta common stock recorded at par value, with the remaining $1,301,061 of the amount being recognized as an adjustment within Kineta’s Additional paid-in capital. All of the outstanding equity of Kineta at the Effective Time, including these shares issued pursuant to satisfy the net working capital deficit amount permissible in the amended Merger Agreement will be canceled and will cease to exist at the Effective Time in accordance with the agreement